Sagimet Biosciences INC Schedule 13G passive stakes

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 3,626,113 shares, representing 5.93% of Sagimet Biosciences Inc.'s common stock.

BlackRock, Inc. has reported beneficial ownership of 7.8% of Sagimet Biosciences Inc.'s Class A Stock as of June 30, 2026.

KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC have filed an early exit Schedule 13G, reporting zero beneficial ownership in Sagimet Biosciences Inc. due to their planned termination.

Woodline Partners LP has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A Common Stock.

Point72 Asset Management and its affiliates have reported a complete divestment of their Series A Common Stock in Sagimet Biosciences Inc., holding 0% as of June 30, 2025.

Woodline Partners LP has reported a significant 8.3% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A Common Stock.

AP11 Limited and Ascletis Pharma Inc. have filed an amendment to their Schedule 13G, reporting a passive beneficial ownership of 4.9% in Sagimet Biosciences Inc.'s Series A common stock.

AP11 Limited and Ascletis Pharma Inc. have jointly disclosed a 5.4% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A common stock as of December 31, 2023.

Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a beneficial ownership of 5.7% in Sagimet Biosciences Inc.'s Series A Common Stock, totaling 1,755,143 shares.

New Enterprise Associates 13, L.P. and its affiliated entities and individuals have filed an amended Schedule 13G, declaring no beneficial ownership in Sagimet Biosciences, Inc. as of March 31, 2025.

Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a beneficial ownership of 4.32% of Sagimet Biosciences Inc.'s Series A common stock as of December 31, 2024.